NCT06141564Active, not recruiting
Detect and Expunge Concealed Tumors of the Liver
Molecular and Immunological Signatures in Recurrent Hepatocellular Carcinoma (HCC)
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
The investigators long-term goal is to identify molecular and immunological signatures that can be used as biomarkers to accurately predict early recurrence and inform immunotherapeutic strategies in patients with hepatocellular carcinoma (HCC) after hepatectomy. As an initial step toward this long-term investigation, represented by this proposal, the investigators aim to comprehensively and globally describe the patterns of autoantibody expressions, the possible role in disease outcomes, and the relationship between these autoantibodies to tumor-specific/tumor-associated antigens by histologic examination as well as to peripheral immune characteristics in HCC patients with or without recurrence after surgery.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 360 (estimated)
- First submitted
- 14 Nov 2023
- Start date
- 16 Oct 2023
- Primary completion date
- 22 Dec 2026
- Lead sponsor
- Johns Hopkins University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06141564
What you commit to
- Study type: Observational
- Planned participants: 360
- From 16 Oct 2023 to the primary completion date, 22 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any serious or active medical or psychiatric illness, which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol
- Known HIV positive
Lab values
- Having any autoimmune diseases based on clinical and/or laboratory availabilities
Other
- Individuals who cannot, do not want to, or refused to sign the informed consent form (ICF)
- Documentation was not adequate
- Taking immunosuppressants
Who the study is looking for
- Provision of signed and dated informed consent form
- Collection of biosamples at baseline (sera, liver cancer and non liver cancer tissues, Peripheral blood mononuclear cells (PBMCs)) each of the 3-month interval follow ups (serum and PBMCs) for a total of 4 during the study follow up duration 1 year post-hepatectomy.
- Early-stage HCC eligible for hepatectomy for curative intention. Early HCC (Stage A) is limited to a single tumor \<5 cm in diameter or three tumors that are each \<3cm.
- Stated willingness to comply with all study procedures and availability for the duration of the study and up to 3 years post-study follow up
- Adults aged 18 or older
- Both genders and all ethnicities
- Willingness to give written, informed consent to be enrolled into the study database
- Reside in Vietnam at the time of study and provides contact information (email and/or cell phone number for texting)
- No prior or current treatment of HCC
- No cancer history within 5 years
- No participation in other trial for HCC Treatment
- No significant hepatic decompensation
- No hepatorenal syndrome
- Alpha fetoprotein (AFP) test labs within 90 days irrespective of AFP titer
- Two phone numbers and personal identification numbers (CMND number)
- No known AIDS related diseases
- No significant co-morbid conditions with life expectancy \<2 years
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| 108 Military Central Hospital Coordinator of this site? Confirm its status | Hanoi | Vietnam | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.